Each opioid treatment program shall
will have
written procedures for toxicology screening that include, at a minimum:
(A) Requirement that an initial toxicology
screening be performed for each prospective patient as part of the documented
physical evaluation completed by a physician prior to admission. The results of
all tests must
are
to be received within fourteen days following admission.
(B) Requirement that a toxicology screening
be performed
monthly for each patient
pursuant to
42 C.F.R.
8.12(f)(6).
(1) This requirement may be reduced
to two toxicology screenings per quarter if the patient has had more than
twenty-four consecutive months of negative screens.
(2) The failure of a toxicology
screening due to illicit drug use shall result in a return to monthly
screening.
(C)
Requirement that programs shall have a
standing physician's order for patient toxicology screening.
(D) Requirement that any urine screen sent in
for confirmation be performed by a laboratory that is in compliance with all
"Clinical Laboratory Improvement Amendments"
per
under 42 C.F.R.
493.
(E) Requirement that
toxicology screening be conducted in a manner to minimize falsification and
that sample collection procedures include the following:
(1) Each specimen collection will be
monitored.
(2) Each sample
shall
will be
labeled to reflect the identification of the person from whom it was obtained
and reflect the date the sample was obtained.
(F) Requirements that each toxicology
screening include, at a minimum
, analysis for the
following:
(1) Opiates, including prescription
opioid analgesics as defined in section
3719.01 of the Revised Code,
heroin, and fentanyl;
(2)
Methadone;
(3)
Amphetamines;
(4)
Cocaine;
(5)
Barbiturates;
(6)
Marijuana;
(7) Benzodiazepines, as
defined in section 3719.01 of the Revised Code;
and,
(8) Buprenorphine.
(G) Results of toxicology screening
shall
will be
reviewed by the program staff with the patient with documentation of such and a
copy of the results placed in the patient's file, in accordance with the
requirements of rule
5122-27-04 of the Administrative
Code.
(H) Provisions for ensuring
that presumptive laboratory results are distinguished from confirmatory
laboratory results.
(I) The program shall have a policy
for the discontinuation of medication maintenance for individuals who test
positive for illicit drugs, which shall include provisions for continuing to
provide counseling and other rehabilitation services, or referral to another
provider.
Notes
Ohio Admin. Code
5122-40-11
Effective:
1/31/2025
Five Year Review (FYR) Dates:
10/31/2024 and
01/31/2030
Promulgated
Under: 119.03
Statutory
Authority: R.C. 5119.37
Rule
Amplifies: R.C. 5119.37
Prior
Effective Dates: 07/01/2001, 10/01/2003, 06/01/2017, 01/01/2019, 04/10/2020
(Emer.)
